ThaiPR.NET https://www.thaipr.net/location/tel-aviv-israel-and-raleigh-n-c Press Release Distribution Center of Thailand Fri, 17 Apr 2026 17:23:52 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations]]> https://www.thaipr.net/en/health_en/3131868 Thu, 09 Dec 2021 08:04:56 +0700 health_en https://www.thaipr.net/en/health_en/3131868 Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of concern Regulatory update Opaganib global Phase 2/3 […]

The post RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results]]> https://www.thaipr.net/en/health_en/3130445 Fri, 03 Dec 2021 16:02:13 +0700 health_en https://www.thaipr.net/en/health_en/3130445 RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation, opaganib and RHB-107’s unique host-targeted mechanisms of action hold potential versus Omicron and other variants – Phase 2/3 study sub-population analysis demonstrated a 62% reduction in mortality in moderately severe hospitalized patients; Data packages […]

The post RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients]]> https://www.thaipr.net/en/health_en/3122773 Wed, 17 Nov 2021 08:10:00 +0700 health_en https://www.thaipr.net/en/health_en/3122773 – Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care – Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose selection, expected in Q1/ 22 – RHB-107 is a novel, investigational antiviral […]

The post RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients]]> https://www.thaipr.net/en/health_en/3106217 Wed, 06 Oct 2021 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3106217 62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm (7 deaths in the 117-patient opaganib arm vs. 21 deaths in the 134-patient placebo arm; nominal p-value=0.019) 21% statistically significant efficacy benefit with opaganib in reaching room air by Day 14, the study primary endpoint […]

The post RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval]]> https://www.thaipr.net/en/health_en/3098458 Wed, 15 Sep 2021 08:20:00 +0700 health_en https://www.thaipr.net/en/health_en/3098458 The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a novel antiviral serine protease inhibitor targeting human cell factors, is expected to […]

The post RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma’s Opaganib Demonstrates Significant Decrease of Kidney Fibrosis]]> https://www.thaipr.net/en/health_en/3096842 Fri, 10 Sep 2021 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3096842 – COVID-19 and long COVID patients are at increased risk of developing kidney damage – Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model – Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to end-stage renal failure – Opaganib is a novel, late clinical-stage oral pill […]

The post RedHill Biopharma’s Opaganib Demonstrates Significant Decrease of Kidney Fibrosis appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021]]> https://www.thaipr.net/en/health_en/3096186 Thu, 09 Sep 2021 08:05:00 +0700 health_en https://www.thaipr.net/en/health_en/3096186 – Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged ≥ 65 years – Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placebo were evaluated across high and low opioid dosages – Movantik is the U.S. […]

The post RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights]]> https://www.thaipr.net/en/health_en/3091725 Mon, 30 Aug 2021 08:10:00 +0700 health_en https://www.thaipr.net/en/health_en/3091725 – Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance 1  of approximately $71.5 million as of June 30, 2021 – Record Talicia® quarterly prescription volume up more than 10%; Movantik® quarterly new prescriptions up 5.6%; Talicia and Movantik coverage expanded to 8 and 9 out of 10 commercially insured Americans, […]

The post RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn’s]]> https://www.thaipr.net/en/health_en/3089823 Tue, 24 Aug 2021 13:45:00 +0700 health_en https://www.thaipr.net/en/health_en/3089823 U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent protection until 2035 Opaganib’s 475-patient global Phase 2/3 study in severe COVID-19 approaching completion with upcoming top-line results Opaganib also undergoing two oncology Phase 2 U.S. studies as well as several development programs for inflammatory and viral indications, including Ebola Continued […]

The post RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn’s appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill Biopharma’s Opaganib Inhibits COVID-19 Variants in Preclinical Study]]> https://www.thaipr.net/en/health_en/3070129 Tue, 29 Jun 2021 12:50:00 +0700 health_en https://www.thaipr.net/en/health_en/3070129 Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity    Opaganib’s unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect against other emerging variants, including the Delta (Indian) variant Completion of opaganib’s global fully enrolled 475-patient Phase 2/3 study in hospitalized […]

The post RedHill Biopharma’s Opaganib Inhibits COVID-19 Variants in Preclinical Study appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill’s Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue]]> https://www.thaipr.net/en/health_en/3013247 Wed, 23 Dec 2020 13:53:24 +0700 health_en https://www.thaipr.net/en/health_en/3013247 Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety data from 155 treated patients Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021 Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected […]

The post RedHill’s Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue appeared first on ThaiPR.NET.

]]> <![CDATA[RedHill’s Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model]]> https://www.thaipr.net/en/health_en/3011251 Fri, 18 Dec 2020 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3011251 Acute respiratory distress syndrome (ARDS)-induced thrombosis (blood clotting) may occur in up to one-third of COVID-19 patients requiring ICU admission and is a contributing cause of mortality Opaganib demonstrated reduced thrombosis in a preclinical model of ARDS Opaganib has also been shown to inhibit SARS-CoV-2 viral replication as well as pro-inflammatory markers in relevant preclinical […]

The post RedHill’s Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model appeared first on ThaiPR.NET.

]]>